Bizacumen Inc., Nov 2009, Pages: 436
Growth in prostatecancer therapies can be attributed to the increase in number of prostatecancer incidences in men aged more than 60 years. Given the longevity of an average individual
Expert Reviews Ltd, May 2011, Pages: 202
This Special Focus Issue of the peer-reviewed journal Expert Review of Endocrinology and Metabolism brings together experts in the fields of hormone dependent- breast and prostatecancer
Datamonitor, March 2011, Pages: 34
Introduction
Over the forecast period, prostatecancer incident cases will increase in all of the seven major markets. These increases are most likely to be as a result of an aging population who
BioPharm Reports (VennBio Ltd.), Feb 2011, Pages: 95
The prostatecancer immunotherapy pipeline is showing rapid development. Currently, there are 30 candidates in the pipeline (16 vaccines and 14 therapeutic antibodies), and one prostatecancer
Bioseeker, Feb 2011
"Analytical Tool - ProstateCancer" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in prostatecancer R&D and business development. It is at the same
Bioseeker, July 2011, Pages: 2820
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and ProstateCancer and by the mechanism/target/effect of Cancer Vaccines. Each of these three individual parts
Bioseeker, Oct 2010, Pages: 2410
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and ProstateCancer and by the mechanism/target/effect of Cancer Vaccines. Each of these three individual
Bioseeker, March 2011, Pages: 2553
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and ProstateCancer and by the mechanism/target/effect of Cancer Vaccines. Each of these three individual
Bioseeker, Oct 2010, Pages: 2107
This triple analysis focuses on cancer drug development strategies in both Pancreatic Cancer and ProstateCancer and by the mechanism/target/effect of Cancer Vaccines. Each of these three individual
Bioseeker, July 2011, Pages: 3074
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lung Cancer and ProstateCancer. Each of these three individual parts is evaluated according to standardized
Bioseeker, July 2011, Pages: 3217
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Lung Cancer and ProstateCancer. Each of these three individual parts is evaluated according to standardized
Bioseeker, July 2011, Pages: 2771
This triple analysis focuses on cancer drug development strategies in Lung Cancer, Pancreatic Cancer and ProstateCancer. Each of these three individual parts is evaluated according to standardized
Bioseeker, March 2011, Pages: 2807
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Colorectal Cancer and ProstateCancer. Each of these three individual parts is evaluated according
Bioseeker, May 2010, Pages: 2361
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Pancreatic Cancer and ProstateCancer. Each of these three individual parts is evaluated according
Bioseeker, March 2011, Pages: 2504
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Pancreatic Cancer and ProstateCancer. Each of these three individual parts is evaluated according
Bioseeker, Sep 2011, Pages: 3441
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (ProstateCancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific
Bioseeker, Nov 2011, Pages: 2403
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (ProstateCancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific
Bioseeker, Dec 2011, Pages: 3114
This triple analysis focuses on cancer drug development strategies in ProstateCancer and by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines. Each of these three individual
Bioseeker, Jan 2012, Pages: 3201
This triple analysis focuses on cancer drug development strategies in ProstateCancer and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines. Each of these three individual
Bioseeker, Sep 2011, Pages: 4105
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and ProstateCancer and by the compound strategy of Antibodies. Each of these three individual parts